Oncolytic virus-induced activation of antitumor immunity and combination with cancer immunotherapy

DOI Web Site 17 References

Bibliographic Information

Other Title
  • 腫瘍溶解性ウイルスによる抗腫瘍免疫の活性化とがん免疫療法との併用

Abstract

Much attention has been focused on oncolytic viruses, which specifically infect and kill tumor cells without apparent cytotoxicity in normal cells, as a novel anticancer agent. In 2021, a recombinant oncolytic herpesvirus simplex virus （HSV）-1 was approved in Japan（conditional and time-limited approval）. Recent studies demonstrated that oncolytic viruses induce not only activation of innate immunity, but also release of neoantigens and damage-associated molecular patterns（DAMPs） from infected tumor cells, leading to efficient activation of antitumor immunity, which contributes to the antitumor effects of oncolytic viruses. In addition, several studies reported that combination therapy of oncolytic viruses and cancer immunotherapy, including immune checkpoint inhibitors, exhibits superior synergistic therapeutic effects on various types of cancers. In this review, we introduce oncolytic virus-mediated activation of antitumor immunity and combination therapy with cancer immunotherapy.

Journal

  • Drug Delivery System

    Drug Delivery System 38 (1), 24-30, 2023-01-25

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

References(17)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top